

University of Michigan Department of Radiation Oncology Division of Radiation Physics

Special Procedures Rotation I/II SBRT, SRS, TBI, and TSET

Resident:
Rotation staff mentor/ advisor: _Scott Hadley, Kwok Lam, and Dale Litzenberg
Rotation Durations: 4 months (2 months + 2 months) Rotation Dates:

A medical physics resident in radiation oncology at the University of Michigan will be expected to demonstrate the following competencies associated with special procedures. These are considered the minimum standards. Resident should complete the list of assignment during his/her rotations.

Contents Outline

Knowledge Factors

- List of reading assignments
- Read and understand relevant AAPM Task Group reports.

Practical Factors

- Observe SRS and SBRT simulation
- SRS and SBRT treatment planning
- Stereotactic pre-treatment QA
- Perform TBI simulation and calculation
- Perform TSET output check

Knowledge Factors – List of reference

Short list of useful references (this is by far not a comprehensive list):

- AAPM Task Group #29, "The physical aspects of total and half body photon irradiation."
- AAPM Task Group #30, "Total skin electron therapy: Technique and dosimetry."
- AAPM Task Group #42, "Stereotactic radiosurgery."
- AAPM Task Group #101, "Stereotactic body radiation therapy"
- AAPM Task Group #155, "Small Fields and Non-Equilibrium Condition Photon Beam Dosimetry"
- The Modern Technology of Radiation Oncology, Editor J. Van Dyk, Medical Physics Publishing, Copyright 1999.
- B.E. Pollack, "Stereotactic radiosurgery for Arteriovenous Malformations", Neurosurgery Clinics of North America, Vol. 10 (2) 281-290 (1999).

- L. Ma *et al.*, "Comparative analyses of linac and Gamma Knife radiosurgery for trigenminal neuralgia treatments, Phys. Med. Biol. 50, 5217-5227 (2005).
- M. Fuss *et al.*, "Stereotactic body radiation therapy: An ablative treatment option for primary and secondary liver tumors", Annals of Surgical Oncology, 11 (2) 130-138 (2004).
- K.K. Herfarth *et al.*, "Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial", Journal of Clinical Oncology, 19 (1) 164-170 (2001).
- Ten Haken RK, Diaz RF, McShan DL, Fraass BA, Taren JA, Hood TW: From manual to computerized planning for 125-I stereotactic brain implants. Int J Rad Onc Biol Phys, 15:467-480, 1988.
- Title 10 of the Code of Federal Regulations Part 35 Subpart 600 35.600, .610, .615, .635, .645, .655

Knowledge Factors - SBRT	Discuss the rationale for SRS treatments for the treatment of malignant and
	benign conditions, as well as common prescriptions.
Demonstrate an understanding of TG-101.	Signature / Date
Signature / Date	
	Discuss commissioning and issues related to the clinical commissioning and
Discuss the rationale for SBRT treatments, common treatment sites, and	maintenance of an SRS program (e.g., accurate localization, mechanical
typical dose and fractionation schemes	precision, accurate and optimal dose distribution, and patient safety);
Signature / Date	Signature / Date
Discuss and demonstrate an understanding of the immobilization and	Discuss the stereotactic localization of a target (e.g., on the basis of
localization systems for SBRT treatments;	angiography as opposed to CT and MRI) and how the accuracy of this
Signature / Date	localization is measured.
	Signature / Date
Discuss the use of simulation imaging for SBRT target definition,	
including multi-modality imaging and 4D imaging for cases requiring	Demonstrate an understanding of the alignment of coordinate systems (e.g.,
motion management.	target frame of reference with linac frame of reference) and how the
Signature / Date	mechanical precision of this alignment is measured.
	Signature / Date
Discuss treatment planning objectives for SBRT treatments, including	Demonstrate an understanding of the in-house procedures and
dose limits, dose heterogeneity, dose gradient and fall-off, and beam	documentation.
geometry.	Signature / Date
Signature / Date	
	Demonstrate an understanding of pre-treatment QA for SRS systems,
Demonstrate an understanding of the in-house procedures and	including linac-based and Co-60 SRS techniques.
documentation. This should include a discussion of treatment	Signature / Date
verification and delivery of SBRT, as well as use of in-room imaging.	
Signature / Date	Demonstrate an understanding of the equipment required to acquire SRS
	related measurements (e.g., small field dosimetry).
Demonstrate an understanding of the equipment required to acquire	Signature / Date
SBRT related measurements (i.e. small field dosimetry).	
Signature / Date	Knowledge Factors – TBI
Demonstrate an understanding of how to commission and implement a	Demonstrate an understanding of TG-29.
new SBRT program.	Signature / Date
Signature / Date	
	Discuss the rationale for TBI treatments for the treatment of malignant and
Knowledge Factors – SRS	Leading the fationale for 131 treatments for the treatment of manighant and

Demonstrate an understanding of TG-42, including a comparison

between linac-based and Co-60 gamma SRS.

Signature / Date

benign conditions,	as well as common prescriptions.			
Signature / Date				
Discuss commission	oning and issues related to the clinical commissioning and			
maintenance of an	SRS program (e.g., accurate localization, mechanical			
precision, accurate	e and optimal dose distribution, and patient safety);			
Signature / Date				
	tactic localization of a target (e.g., on the basis of			
	posed to CT and MRI) and how the accuracy of this			
localization is mea	isured.			
Signature / Date				
	nderstanding of the alignment of coordinate systems (e.g.,			
-	erence with linac frame of reference) and how the			
	ion of this alignment is measured.			
Signature / Date				
	nderstanding of the in-house procedures and			
documentation.				
Signature / Date				
	nderstanding of pre-treatment QA for SRS systems,			
including linac-ba	sed and Co-60 SRS techniques.			
Signature / Date				
	nderstanding of the equipment required to acquire SRS			
	ents (e.g., small field dosimetry).			
Signature / Date				
Knowledge Factors – TBI				
Demonstrate an ur	nderstanding of TG-29.			
Signature / Date	derstanding of 10 2).			
Signature / Date				
Discuss the retien	ala for TRI transments for the transment of malianest and			
benign conditions.	ale for TBI treatments for the treatment of malignant and			
comen conditions.				

Signature / Date

Demonstrate an understanding of TBI prescription and delivery	Practical F	<u> actors – SBRT</u>	
techniques.			
Signature / Date		discuss simulation of SBR	T patients
Discuss commissioning and issues related to clinical commissioning and	Brain	Signature / Date	
maintenance of a TBI program.	Brain	Signature / Date	
Signature / Date	Liver	Signature / Date	
	Liver	Signature / Date	
Demonstrate an understanding of the significance of beam modifiers	Lung	Signature / Date	
commonly used during TBI treatments and how they are clinically	Lung	Signature / Date	
commissioned (e.g., lung/kidney blocks, beam spoilers).	Prostate	Signature / Date	
Signature / Date	Prostate	Signature / Date	
	Spine	Signature / Date	
Knowledge Factors - TSET	Spine	Signature / Date	
Signature / Date	Brain Brain	Signature / Date Signature / Date	
		Signature / Date	
Discuss the rationale for TSET treatments for the treatment of malignant	Liver	Signature / Date	
and benign conditions.	Liver	Signature / Date	
Signature / Date	Lung	Signature / Date	
	Lung	Signature / Date	
Demonstrate an understanding of TSET prescription and delivery	Prostate	Signature / Date	
techniques.	Prostate	Signature / Date	
Signature / Date	Spine	Signature / Date	
	Spine	Signature / Date	
Discuss commissioning and issues related to clinical commissioning and	D 6	IDDE O A	
maintenance of a TSET program.	Perform pre-S		
Signature / Date	Signature / Dat		
	Signature / Dat		
Discuss and demonstrate an understanding of the significance of the	Signature / Dat		
TSET MU calculation, including the B-factor and how it is measured.	Signature / Dat	re e	
Signature / Date			
		participate with day one S	BRT treatments, including C
Demonstrate an understanding of the significance of beam modifiers	alignment		
commonly used during TSET treatments (e.g., shields, beam scatter).	Signature / Dat		
Signature / Date	Signature / Dat		
	Signature / Dat		
	Signature / Dat	re e	

<u>Practical Factors – SRS</u>	Perform TBI calculation, including where necessary, lung block calculations
	and QA.
Observe and discuss simulation of frame-based SRS patients.	Signature / Date
Signature / Date	Signature / Date
Signature / Date	Signature / Date
	Signature / Date
Observe and discuss simulation of frameless SRS patients.	
Signature / Date	Setup TBI electronic chart and enter data into ARIA.
Signature / Date	Signature / Date
Signature / Date	Signature / Date
Signature / Date	Signature / Date
	Signature / Date
Discuss and participate in planning of SRS patients.	
Signature / Date	Observe and participate in TBI treatment, treatment verification, and in vivo
Signature / Date	measurements, where applicable.
Signature / Date	Signature / Date
Signature / Date	Signature / Date
	Signature / Date
Perform SRS plan and MU secondary checks.	Signature / Date
Signature / Date	
Signature / Date	Practical Factors – TSET
Signature / Date	
Signature / Date	Participate in TSET beam calibration and output check.
	Signature / Date
Perform SRS pre-treatment QA.	
Signature / Date	Participate in TSET planning and plan verification.
Signature / Date	Signature / Date
Signature / Date	Signature / Date
Signature / Date	Signature / Date
Signature / Date	
Practical Factors – TBI	Setup TSET electronic chart and enter data into ARIA.
Participate in TBI simulation – with or w/o lung blocks, but must include	Signature / Date
one of each.	Signature / Date
Signature / Date	Signature / Date
Signature / Date	
Signature / Date	Observe and participate in TSET treatment and in vivo measurements.
Signature / Date	Signature / Date
Manufact Date	Signature / Date
	Signature / Date